CORDIS
EU research results

CORDIS

English EN
An integrated concept of tumor metastasis: implications for therapy

An integrated concept of tumor metastasis: implications for therapy

Objective

From many perspectives our concept of the process of metastasis is inadequate and needs to be revised. In particular, the potential impact of recent ideas about the cellular basis of tumor growth (cancer stem cells) and the establishment by remote tumors of special permissive microenvironments in target organs prior to metastasis (metastatic niches) remains to be explored. In the TuMIC project we will use novel experimental approaches to integrate these newly emerging principles and ideas with the different hypotheses that have until now tried to explain the process of metastasis. Specifically we aim to understand how cancer stem cells behave in and contribute to metastasis, and how networks and pathways that are known to regulate metastasis affect their properties. Further objects are to determine how a permissive microenvironment for metastasis formation is established in given organs, how this contributes to determining patterns of metatasis, and how these microenvironments interact with cancer stem cells. These studies will facilitate the development of an improved and more accurate concept about the process of metastasis. In turn, this will have fundamental ramifications for the way in which novel anti-cancer therapies are designed, and most importantly should provide important new insights into how cancer and in particular metastatic disease can be successfully treated. With this in mind we will also perform preclinical studies that build on TuMIC findings with the aim of developing novel anti-cancer therapies.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

Address

Seminarstrasse 2
69117 Heidelberg

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 501 388,88

Administrative Contact

Norbert Huber (Dr.)

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITAT BASEL

Switzerland

EU Contribution

€ 258 000

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 258 000

CANCER RESEARCH UK

United Kingdom

EU Contribution

€ 170,44

FONDATION DU CENTRE PLURIDISCIPLINAIRE D'ONCOLOGIE

Switzerland

EU Contribution

€ 159 176,64

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

Netherlands

EU Contribution

€ 253 200

UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II

Italy

EU Contribution

€ 241 200

KRAEFTENS BEKAEMPELSE

Denmark

EU Contribution

€ 258 000

VIB

Belgium

EU Contribution

€ 258 000

ACTELION PHARMACEUTICALS LTD

Switzerland

EU Contribution

€ 248 150

INSTITUT CURIE

France

EU Contribution

€ 219 600

FORSCHUNGSZENTRUM KARLSRUHE GMBH

Germany

EU Contribution

€ 583,12

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 257 829,56

UNIVERSITE DE FRIBOURG

Switzerland

EU Contribution

€ 85 886,36

Project information

Grant agreement ID: 201662

Status

Closed project

  • Start date

    1 April 2008

  • End date

    31 March 2012

Funded under:

FP7-HEALTH

  • Overall budget:

    € 4 180 192,60

  • EU contribution

    € 2 999 185

Coordinated by:

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

Germany